Livagen (KEDA) is studied in vitro as a chromatin-directed short-peptide probe. In lymphocyte and hepatocyte cultures it has been reported to induce chromatin decondensation (de-heterochromatinisation), activating ribosomal genes and releasing genes repressed by condensation of euchromatic regions, used experimentally to study gene-expression and protein-synthesis programmes in cultured cells.
It is a tool for probing chromatin-level transcriptional regulation in immune and hepatic cell systems. Observed effects depend on concentration, model system and exposure conditions.
Applications in Research
- In-vitro lymphocyte chromatin-activation and ribosomal-gene studies
- Hepatocyte gene-expression and protein-synthesis research
- Reference probe for short-peptide transcriptional regulation
Specifications Summary
| Parameter |
Typical Value / Range |
| Purity (HPLC) |
≥ 99% |
| Appearance |
White to off-white lyophilised powder |
| Molecular Weight |
461.47 g/mol |
| Peptide Type |
Synthetic tetrapeptide |
| Solubility |
Water, buffered aqueous solutions |
| Storage |
–20 °C, desiccated, dark |
| Pack Size |
20 mg (total) |
Precautions & Notes
- Experimental behaviour is dependent on concentration, model system and exposure conditions
- Appropriate experimental controls are recommended
- Prolonged exposure to light, elevated temperature or aqueous environments may reduce stability
- Intended strictly for laboratory research use; not for human or veterinary application
References
Khavinson VKh, Popovich IG, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053.
https://www.mdpi.com/1420-3049/26/22/7053
PubChem Compound Summary, CID 87919683 (Lys-Glu-Asp-Ala).
https://pubchem.ncbi.nlm.nih.gov/compound/87919683
Keywords: Livagen, KEDA, short peptide, synthetic tetrapeptide, chromatin
